Eficácia e segurança de mebutato de ingenol no tratamento da queratose actínica: Revisão sistemática e meta-análise.

João Costa; Rita Sousa; Joana Alarcão; António Vaz Carneiro; Paulo Filipe

doi:10.29021/spdv.72.2.243

João Costa Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Laboratório de Farmacologia Clínica e Terapêutica. Faculdade Medicina Universidade Lisboa.
Rita Sousa Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Faculdade Medicina Universidade Lisboa.
Joana Alarcão Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Laboratório de Farmacologia Clínica e Terapêutica. Faculdade Medicina Universidade Lisboa.
António Vaz Carneiro Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Laboratório de Farmacologia Clínica e Terapêutica. Faculdade Medicina Universidade Lisboa.
Paulo Filipe 3. Serviço de Dermatologia do Centro Hospitalar Lisboa Norte e Unidade de Investigação em Dermatologia. Instituto de Medicina Molecular. Faculdade de Medicina. Universidade de Lisboa. Lisboa, Portugal.

DOI: https://doi.org/10.29021/spdv.72.2.243

Palavras-chave: Mebutato de ingenol, Queratose actínica, Revisão sistemática, Meta-análise.

Resumo

Introdução: A queratose actínica é a lesão pré-maligna mais frequente. A abordagem terapêutica dos doentes com múltiplas lesões envolve terapêuticas de campo.

Objetivo: Avaliar a eficácia e segurança de mebutato de ingenol, um novo medicamento destinado à terapêutica tópica de campo.

Desenho: Revisão sistemática e meta-análise dos ensaios clínicos controlados e aleatorizados (RCTs).

Fontes bibliográficas: Medline e Cochrane Library (junho 2014).

Seleção dos estudos: A seleção e avaliação dos RCTs foram feitas de forma independente.

Análise quantitativa: Meta-análise de efeitos aleatórios. A heterogeneidade foi avaliada com o teste I² .

Resultados: Foram incluídos 6 ensaios (n=1.492) versus placebo. Mebutato de ingenol esteve associado a uma possibilidade de um doente ter remoção completa das lesões 17 (IC95%: 9 a 31; I²=0%) e 8,5 (IC95%: 5 a 15; I²=0%) vezes superior, comparativamente ao placebo, no rosto/couro cabeludo e no tronco/extremidades, respetivamente. A incidência de eventos adversos relacionados com o tratamento foi superior no grupo mebutato de ingenol (+23%, IC95%: 11 a 35%), sem diferenças entre grupos na taxa de abandono por eventos adversos.

Conclusões: Mebutato de ingenol é eficaz no tratamento da queratose actínica. Comparativamente às restantes terapêuticas de campo disponíveis em Portugal, o seu valor terapêutico advém do favorável perfil de segurança e tolerabilidade, da simplicidade e curta duração do esquema terapêutico e da possibilidade de tratar de forma diferenciada as lesões de acordo com a localização anatómica (individualização da terapêutica).Estudos futuros deveriam comparar diretamente as diferentes opções terapêuticas e avaliar a efetividade das mesmas no mundo real.

Downloads

Não há dados estatísticos.

Biografias Autor

João Costa, Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Laboratório de Farmacologia Clínica e Terapêutica. Faculdade Medicina Universidade Lisboa.

João Costa was born on 1974 in Portugal. He receive is licensure in Medicine (School of Medicine, University of Lisbon) in 1998 and he practice as a General practitioner between 1999 to 2000. In 2006 he became specialist in neurology and later on in clinical neurophysiologist and in clinical pharmacology. He received clinical research training in the Walton Centre for Neurology and Neurosurgery (WCNN) NHS Trust, Liverpool, UK and in the Neurology Department of the Hospital Clínic of Barcelona, Spain. Currently he practice medicine in Hospital da Luz, Lisbon, Portugal. After finishing his licensure, he got the following academic degrees and titles: Master of Neurosciences (University of Lisbon); Master of Neurological electrodiagnosis (University of Barcelona); and Doctor of Medicine, Discipline of Neurology (University of Lisbon). He had a Postdoctoral Research Fellowship by CIBERNED to work for a year at Hospital Clínic of Barcelona, Spain. His major current positions are: Professor of Clinical Pharmacology and Therapeutics at School of Medicine, University of Lisbon; Coordinator Editor of the Cochrane Movement Disorders Group; Coordinator Director of the Portuguese Cochrane Branch of the Iberoamerican Cochrane Network; Principal Investigator at the Clinical Pharmacology Unit and at the Translational Clinical Physiology Unit of the Institute of Molecular Medicine (Lisbon, Portugal), and Member of the Clinical Pharmacology College of the Portuguese General Medical Council. He is ad-hoc reviewer for 12 international journals. He has published 110 full papers in peer review journals. He presented 144 communications at scientific conferences. He has written 5 book chapters and 7 national clinical guidelines. He has received 10 Awards and Distinctions as first author/investigator by national and international institutions.

António Vaz Carneiro, Centro de Estudos de Medicina Baseada na Evidência (CEMBE). Laboratório de Farmacologia Clínica e Terapêutica. Faculdade Medicina Universidade Lisboa.

António Vaz Carneiro, MD, PhD, FACP

FACULTY OF MEDICINE UNIVERSITY OF LISBON
Head, Center for Evidence Based Medicine

Executive-Director, Institute for Advanced Education - Head, Main Library - Center for Information and Documentation

Chair, BEME Review Editorial Board, AMEE

Director, Portuguese Collaborating Center of the Iberoamerican Cochrane Network

Referências

Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: Barriers and opportunities. J Am Acad Dermatol. 2013; 68(1 Suppl 1):S2-9.

Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000; 42(1 Pt 2):23-4.

Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspetive. Arch Dermatol. 1991; 127(7):1029–1031.

Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007; 33(9):1099-101.

Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 2000; 42(1 Pt 2):11-7.

Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007; 156 Suppl 3:8-12.

Williams H, Svensson A, Diepgen T, Naldi L, Coenraads PJ, Elsner P et al.; European Dermato-Epidemiology Network (EDEN). Epidemiology of skin diseases in Europe. Eur J Dermatol. 2006; 16(2):212-8.

Lucas R, McMichael T, Smith W, Armstrong B. Solar ultraviolet radiation- global burden of disease from solar ultraviolet radiation- WHO report. 2006. Report No.: Environmental Burden of Disease Series N 13.

Massa A, Alves R, Amado J, Matos E, Sanches M, Selores M et al. [Prevalence of cutaneous lesions in Freixo de Espada à Cinta]. Ata Med Port. 2000; 13(5-6):247-54

de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007; 156(2):222-30.

Stockfleth E, Terhorst D, Braathen L, Cribier B, Cerio R, Ferrandiz C et al., on behalf of the European Dermatology Forum. European Dermatology Forum. [Online]; 2010 [citado a: 2012 10 25. Disponível a partir: http://www.euroderm.org/images/stories/guidelines/guideline_Management_Actinic_Keratoses-update2011.pdf.

Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008; 18(6):651-9.

European public assessment report (EPAR) do Picato®, disponível em http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Product_Information/human/002275/WC500135327.pdf (Acedido em 2/07/2014)

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.

Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S. eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Disponível a partir de http://handbook.cochrane.org/

Cochrane Review Manager Software. Version 5.2. Disponível a partir: http://tech.cochrane.org/Revman.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557–560.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.

Berman B, Goldenberg G, Hanke CW, Tyring SK, Werschler WP, Knudsen KM et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol. 2014; 13(6):741-7.

Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64.

Tinghög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Ata Derm Venereol. 2008; 88(5):467-73.

Australian Institute of Health and Welfare. Health system expenditures on cancer and other neoplasms in Australia, 2000-01. Canberra: Australian Institute of Health and Welfare; 2005.

Serup J, Lindblad AK, Maroti M, Kjellgren KI, Niklasson E, Ring L et al. To follow or not to follow dermatological treatment--a review of the literature. Ata Derm Venereol. 2006; 86(3):193-7.

Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013; 68(1 Suppl 1):S28-38.

Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013; 149(6):666-70.

Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014; 13(3):269-73.

Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004415

Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013; 169(2):250-9.